More on Depomed (DEPO): The FDA overwhelmingly rejects gabapentin, saying that clinical studies...

|About: Depomed Inc. (DEPO)|By:, SA News Editor

More on Depomed (DEPO): The FDA overwhelmingly rejects gabapentin, saying that clinical studies didn't meet the required study goals. In particular, the agency said three studies didn't show a reduction in the frequency of hot flashes at 12 weeks of treatment, and though the study showed a reduction in the severity, results varied considerably. The decision is surprising, considering that Gabapentin and some antidepressants are already used by some doctors to treat hot flashes even though the medicines aren't approved for that use. Shares remain halted.